News
DTIL
7.46
+0.40%
0.03
Weekly Report: what happened at DTIL last week (0810-0814)?
Weekly Report · 7h ago
Precision BioSciences: Buy Rating Reiterated as ARCUS HBV and DMD Catalysts De-Risk Platform; $60 Price Target Maintained
TipRanks · 5d ago
Weekly Report: what happened at DTIL last week (0803-0807)?
Weekly Report · 08/10 09:48
*Precision Biosciences 2Q Loss $32.7M >DTIL
Dow Jones · 08/06 11:01
Press Release: Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 08/06 11:01
Press Release: Precision BioSciences Reports -2-
Dow Jones · 08/06 11:01
*Precision Biosciences 2Q Loss/Shr $1.26 >DTIL
Dow Jones · 08/06 11:01
Press Release: Precision BioSciences Reports -3-
Dow Jones · 08/06 11:01
*Precision Biosciences 2Q Rev $18,000 >DTIL
Dow Jones · 08/06 11:01
Precision BioSciences: Q2 Earnings Snapshot
Barchart · 08/06 06:24
Precision BioSciences Q2 2026 Earnings Preview
Seeking Alpha · 08/05 17:13
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL)
TipRanks · 08/03 10:20
Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 08/03 10:09
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Benzinga · 08/03 09:59
Weekly Report: what happened at DTIL last week (0727-0731)?
Weekly Report · 08/03 09:48
Press Release: Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Dow Jones · 07/31 11:05
Precision BioSciences Announces Key Executive Leadership Changes
TipRanks · 07/27 11:58
Precision BioSciences Names New Operations Chief and CFO
Dow Jones · 07/27 11:34
Precision BioSciences announces key management changes
Seeking Alpha · 07/27 11:18
Precision BioSciences announces changes to its senior leadership team
TipRanks · 07/27 11:15
More
Webull provides a variety of real-time DTIL stock news. You can receive the latest news about Precision Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.